ICML 2025 | Updates from the BRAWM trial: bendamustine, rituximab and acalabrutinib in patients with WM

We’re very pleased with the results of the BRAWM trial. That’s what we’re presenting at the ICML in Lugano currently and the results are very positive. We see the highest response rates ever seen in Waldenström’s for first-line treatments. The complete and very good partial response rate is over 60% and historically the rates have been closer to 20-25% so we’ve actually doubled the complete and very good partial response rate. We see that we’re getting deep responses because complete and very good partial responses are by definition almost very complete responses and we’re also backing this up with very high rates of minimal residual disease negative results in patients’ peripheral blood, not so much in the bone marrow but definitely in the peripheral blood. The MRD negative rates at our first response assessment were very close to 70% to 80%. Now, I think that these results are important. We’ll have to see how it plays out and whether these very deep initial responses translate into longer durations of response. But one thing we’re very excited about, and we’ve looked at this very carefully, is that patients who have very high-risk Waldenström’s, so patients who have mutations of CXCR4 or who have wild-type MYD88, these patients are known to have poor response rates to standard treatments and shorter response durations. These patients behave very similarly to all other patients in our trial. They had the same response rate; there was no different response rate or MRD rate that we were able to document in these high-risk subgroups. So it could be that patients with higher-risk Waldenström’s would be ideal candidates for this type of combination treatment where we combine several different treatments together.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.